论文部分内容阅读
目的评价依达拉奉联合奥扎格雷钠对急性脑梗死血脂和血液流变学的影响。方法将入选的急性脑梗死患者120例随机分为治疗组和对照组各60例,对照组用常规治疗方法(复方丹参注射液和奥扎格雷钠注射液静脉滴注,口服肠溶阿司匹林片等);治疗组在常规治疗的基础上加依达拉奉注射液静脉滴注。两组疗程均为4周。观察两组治疗前后临床疗效(神经功能缺损程度改变)及血脂、血液流变学指标的变化。结果治疗组总有效率高于对照组(P<0.05),在血脂、血液流变学水平与对照组比较,差异均有统计学意义(P<0.01)。结论依达拉奉联合奥扎格雷钠能明显改善急性脑梗死患者临床症状和血脂、血液流变学指标。
Objective To evaluate the effect of edaravone and ozagrel on the blood lipids and hemorheology in patients with acute cerebral infarction. Methods A total of 120 patients with acute cerebral infarction were randomly divided into treatment group (60 cases) and control group (60 cases). Patients in control group were treated with conventional treatment (compound Danshen injection and sodium ozagrel, intravenous aspirin tablets, etc.) ). The treatment group received intravenous infusion of edaravone on the basis of routine treatment. Two courses of treatment were 4 weeks. Before and after treatment, the clinical curative effect (changes of neurological deficit) and the changes of blood lipid and hemorheology indexes were observed. Results The total effective rate in the treatment group was higher than that in the control group (P <0.05). There was significant difference in the level of blood lipid and hemorheology between the treatment group and the control group (P <0.01). Conclusion Edaravone combined with ozagrel sodium can significantly improve clinical symptoms, blood lipids and hemorheology in patients with acute cerebral infarction.